Icosavax Valuation

ICVXDelisted Stock  USD 9.02  0.12  1.31%   
At this time, the firm appears to be overvalued. Icosavax retains a regular Real Value of $7.25 per share. The prevalent price of the firm is $9.02. Our model calculates the value of Icosavax from evaluating the firm fundamentals such as Return On Equity of -0.42, return on asset of -0.27, and Shares Owned By Insiders of 3.47 % as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
9.02
Please note that Icosavax's price fluctuation is very steady at this time. Calculation of the real value of Icosavax is based on 3 months time horizon. Increasing Icosavax's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Icosavax is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Icosavax Stock. However, Icosavax's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  9.02 Real  7.25 Hype  9.02 Naive  8.73
The intrinsic value of Icosavax's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Icosavax's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
7.25
Real Value
9.92
Upside
Estimating the potential upside or downside of Icosavax helps investors to forecast how Icosavax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Icosavax more accurately as focusing exclusively on Icosavax's fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
8.329.3210.33
Details
Hype
Prediction
LowEstimatedHigh
9.029.029.02
Details
Naive
Forecast
LowNext ValueHigh
8.738.738.73
Details

Icosavax Total Value Analysis

Icosavax is currently anticipated to have valuation of 547.9 M with market capitalization of 769.04 M, debt of 8.79 M, and cash on hands of 242.8 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Icosavax fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
547.9 M
769.04 M
8.79 M
242.8 M

Icosavax Asset Utilization

One of the ways to look at asset utilization of Icosavax is to check how much profit was generated for every dollar of assets it reports. Icosavax retains a negative application of resources of -0.27 (percent), losing $0.002673 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Icosavax shows how discouraging it operates for each dollar spent on its resources.

Icosavax Ownership Allocation

Icosavax has a total of 50.23 Million outstanding shares. The majority of Icosavax outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Icosavax to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Icosavax. Please pay attention to any change in the institutional holdings of Icosavax as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Icosavax Profitability Analysis

Net Loss for the year was (96.71 M) with loss before overhead, payroll, taxes, and interest of (30.97 M).

About Icosavax Valuation

Our relative valuation model uses a comparative analysis of Icosavax. We calculate exposure to Icosavax's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Icosavax's related companies.
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company was incorporated in 2017 and is headquartered in Seattle, Washington. Icosavax operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.

Icosavax Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares Outstanding39.7 M
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Other Consideration for investing in Icosavax Stock

If you are still planning to invest in Icosavax check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Icosavax's history and understand the potential risks before investing.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account